Celsion Corporation Urges All Shareholders to Vote at the 2021 Annual Meeting to be Held on Friday June 4, 2021
May 27, 2021 08:30 ET
|
Celsion CORP
Calls for All Shareholders to Vote so Quorum Requirement to Hold The Meeting is Met LAWRENCEVILLE, N.J., May 27, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage...
Celsion Corporation Reports First Quarter 2021 Financial Results and Provides Business Update
May 14, 2021 08:00 ET
|
Celsion CORP
Focus on Immuno-Oncology and Next-Generation Vaccines is Supported with a Strong Balance Sheet Conference Call Begins at 10:00 a.m. Eastern Time Today LAWRENCEVILLE, N.J., May 14,...
Celsion Receives $1.85 Million from the Sale of its New Jersey State Net Operating Losses
May 11, 2021 08:00 ET
|
Celsion CORP
Non-Dilutive Funding Strengthens Balance Sheet, Extends Cash Runway Beyond 2024 Sale of an Additional $5.0 Million of State NOLs Expected in Future Years LAWRENCEVILLE, N.J., May 11, 2021 ...
Celsion Corporation to Hold First Quarter 2021 Financial Results and Business Update Conference Call on Friday, May 14, 2021
May 07, 2021 08:30 ET
|
Celsion CORP
LAWRENCEVILLE, N.J., May 07, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines,...
Celsion Management Participates in Alliance Global Partners Virtual Series
April 22, 2021 08:30 ET
|
Celsion CORP
LAWRENCEVILLE, N.J., April 22, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced...
Poster on Celsion Corporation’s Phase I/II OVATION 2 Study Presented at the Society of Gynecologic Oncology Virtual Annual Meeting on Women’s Cancer
April 01, 2021 08:30 ET
|
Celsion CORP
Company reports further strengthening of R0 resection results in patients treated with GEN-1 LAWRENCEVILLE, N.J., April 01, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a...
Celsion Corporation to Hold Year-End 2020 Financial Results and Business Update Conference Call on Friday, March 19, 2021
March 12, 2021 08:45 ET
|
Celsion CORP
LAWRENCEVILLE, N.J., March 12, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines,...
Poster on Celsion Corporation’s Phase I/II OVATION 2 Study to be Presented at the Society of Gynecologic Oncology Virtual Annual Meeting on Women’s Cancer
March 02, 2021 08:45 ET
|
Celsion CORP
LAWRENCEVILLE, N.J., March 02, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines,...
Celsion Corporation Provides Clinical Update on Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer Including Encouraging Interim Resection Scores
February 25, 2021 08:45 ET
|
Celsion CORP
Of 27 patients who completed interval debulking surgery, 80% of those treated with GEN-1 had an R0 resection compared with 58% of control patients, a 38% improvement To date 34 patients, or...
Celsion Announces Publication of Research on Fluorescence Imaging of ThermoDox® Uptake in International Journal of Hyperthermia
November 14, 2019 08:00 ET
|
Celsion CORP
Independent Analysis Confirms Increasing Heating Time + ThermoDox® Improves Tumor Uptake of Drug, which may be visualized by real-time fluorescence imaging Study Confirms that ThermoDox® Can Deliver...